Tech Times | InterMune Up on Esbriet Data Presentation Zacks.com The ASCEND study is evaluating Esbriet in patients suffering from idiopathic pulmonary fibrosis (IPF) in the U.S. Results showed that Esbriet reduced decline in lung function. Moreover, Esbriet demonstrated significant treatment effects in the six ... Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis ... |
